5.7 C
New York
Friday, February 27, 2026

Win For Pfizer? Seagen’s Cancer Combo Therapy Hits Primary Goal In Late-Stage Breast Cancer Study

Seagen Inc (NASDAQ: SGEN) announced that the Phase 3 HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug …

This post was originally published on this site

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

149,472FansLike
396,312FollowersFollow
2,650SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x